Shinya Yamanaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shinya Yamanaka has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Megumi Narita
Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan
7 shared publicationsTomoko Ichisaka
CiRA Foundation, 53 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8397, Japan
7 shared publicationsKazutoshi Takahashi
Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan
6 shared publicationsAkira Watanabe
Department of Life Science Frontiers, Center for iPS Cell Research and Application, Kyoto University, Kyoto 606-8507, Japan
4 shared publications- Hideyuki Okano
Laboratory for Marmoset Models of Brain Diseases, RIKEN Center for Brain Science
4 shared publications - Keisuke Okita
Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan
4 shared publications
Latest Publications
- Open Access
- 8 August 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (8) , 1547-1548
Pluripotent stem cell-based therapies and their path to the clinic
- 8 August 2023
- Published by Elsevier in Stem Cell Reports
- Vol. 18 (8) , 1547-1548
Open AccessPluripotent stem cell-based therapies and their path to the clinic
- Top Cited PapersOpen Access
A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population
- Open Access
- 7 September 2021
- Published by Elsevier in Regenerative Therapy
- Vol. 18, 321-333
First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol
- 7 September 2021
- Published by Elsevier in Regenerative Therapy
- Vol. 18, 321-333
Open AccessFirst-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol
- Top Cited Papers
- 1 October 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 27 (4) , 523-531
Pluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
- 1 October 2020
- Published by Elsevier in Cell Stem Cell
- Vol. 27 (4) , 523-531
Top Cited PapersPluripotent Stem Cell-Based Cell Therapy—Promise and Challenges
- Open Access
- 1 January 2018
- Published by Japan Medical Association in JMA Journal
- Vol. 1 (1) , 6-14
Bringing Induced Pluripotent Stem Cell Technology to the Bedside
Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed into any other cell type. They also act as a human model for understanding the development of every cell and organ in the body. In addition, because they can be prepared from patients, iPSCs offer a unique human model for studying disease development, including many diseases that are generally diagnosed at a late stage of their development. These models have provided new insights on the pathogenesis and new targets to prevent or reverse the disease development process. Indeed, clinical studies on compounds based on drug screening hits in human iPSC disease models have begun. Because of their proliferation and differentiation capacity, iPSCs can also be used to prepare cells for transplantations, and related clinical studies using iPSC-based cell therapies are ongoing. The combination of iPSCs with other technologies or therapeutic strategies is expected to expand their medical benefits. In this review, we consider medical accomplishments based on iPSC research and future ones that can be anticipated.
- 1 January 2018
- Published by Japan Medical Association in JMA Journal
- Vol. 1 (1) , 6-14
Open AccessBringing Induced Pluripotent Stem Cell Technology to the Bedside
Induced pluripotent stem cells (iPSCs) describe somatic cells that have been reprogrammed to the pluripotent state. From a scientific perspective, their discovery has provided a molecular roadmap for turning on and off cell identities, effectively allowing any cell type to have its identity changed into any other cell type. They also act as a human model for understanding the development of every cell and organ in the body. In addition, because they can be prepared from patients, iPSCs offer a unique human model for studying disease development, including many diseases that are generally diagnosed at a late stage of their development. These models have provided new insights on the pathogenesis and new targets to prevent or reverse the disease development process. Indeed, clinical studies on compounds based on drug screening hits in human iPSC disease models have begun. Because of their proliferation and differentiation capacity, iPSCs can also be used to prepare cells for transplantations, and related clinical studies using iPSC-based cell therapies are ongoing. The combination of iPSCs with other technologies or therapeutic strategies is expected to expand their medical benefits. In this review, we consider medical accomplishments based on iPSC research and future ones that can be anticipated.
- Open Access
- 28 March 2017
- Published by Elsevier in EBioMedicine
- Vol. 18, 3-4
New Models for Therapeutic Innovation from Japan
- 28 March 2017
- Published by Elsevier in EBioMedicine
- Vol. 18, 3-4
Open AccessNew Models for Therapeutic Innovation from Japan
- 21 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (2) , 340-345
Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells
Significance: We have previously shown that novel APOBEC1 target 1 (NAT1), which is homologous to the C-terminal two thirds of eukaryotic translation initiation factor 4G (eIF4G), is essential for differentiation of mouse embryonic stem cells (mES cells). In the current study, we demonstrate that Nat1 supports the translation of mitogen-activated protein kinase kinase kinase 3 ( Map3k3 ) and son of sevenless homolog 1 ( Sos1 ). Deletion of Nat1 resulted in decreased protein levels of these factors, resulting in suppression of the Erk and Akt signaling pathway. Forced expression of Map3k3 induced differentiation in Nat1 -null mES cells. Thus Nat1 is involved in the translation of proteins that are required for the differentiation of mES cells.
- 21 December 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 114 (2) , 340-345
Nat1 promotes translation of specific proteins that induce differentiation of mouse embryonic stem cells
Significance: We have previously shown that novel APOBEC1 target 1 (NAT1), which is homologous to the C-terminal two thirds of eukaryotic translation initiation factor 4G (eIF4G), is essential for differentiation of mouse embryonic stem cells (mES cells). In the current study, we demonstrate that Nat1 supports the translation of mitogen-activated protein kinase kinase kinase 3 ( Map3k3 ) and son of sevenless homolog 1 ( Sos1 ). Deletion of Nat1 resulted in decreased protein levels of these factors, resulting in suppression of the Erk and Akt signaling pathway. Forced expression of Map3k3 induced differentiation in Nat1 -null mES cells. Thus Nat1 is involved in the translation of proteins that are required for the differentiation of mES cells.
- 28 October 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (46) , 13057-13062
BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence
Fibrodysplasia ossificans progressiva (FOP) patients carry a missense mutation in ACVR1 [617G > A (R206H)] that leads to hyperactivation of BMP-SMAD signaling. Contrary to a previous study, here we show that FOP fibroblasts showed an increased efficiency of induced pluripotent stem cell (iPSC) generation. This positive effect was attenuated by inhibitors of BMP-SMAD signaling (Dorsomorphin or LDN1931890) or transducing inhibitory SMADs (SMAD6 or SMAD7). In normal fibroblasts, the efficiency of iPSC generation was enhanced by transducing mutant ACVR1 (617G > A) or SMAD1 or adding BMP4 protein at early times during the reprogramming. In contrast, adding BMP4 at later times decreased iPSC generation. ID genes, transcriptional targets of BMP-SMAD signaling, were critical for iPSC generation. The BMP-SMAD-ID signaling axis suppressed p16/INK4A-mediated cell senescence, a major barrier to reprogramming. These results using patient cells carrying the ACVR1 R206H mutation reveal how cellular signaling and gene expression change during the reprogramming processes. Significance The development of iPSCs provides unprecedented opportunities for life sciences, drug discovery, and regenerative medicine. The efficiency of iPSC generation is quite low: typically less than 1% of human primary somatic cells that have received reprogramming factors turn into iPSCs. Previous studies revealed that cellular senescence was a major barrier to iPSC generation. In this study using human FOP mutant cells, we provide evidence that the BMP-SMAD-ID signaling suppressed p16/INK4A-mediated cellular senescence during the early phase in iPSC generation. These results are unexpected because BMP-SMAD signaling has negative effects on the self-renewal of human iPSCs. Here, we show that a human natural mutation increases the efficiency of iPSC generation.
- 28 October 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (46) , 13057-13062
BMP-SMAD-ID promotes reprogramming to pluripotency by inhibiting p16/INK4A-dependent senescence
Fibrodysplasia ossificans progressiva (FOP) patients carry a missense mutation in ACVR1 [617G > A (R206H)] that leads to hyperactivation of BMP-SMAD signaling. Contrary to a previous study, here we show that FOP fibroblasts showed an increased efficiency of induced pluripotent stem cell (iPSC) generation. This positive effect was attenuated by inhibitors of BMP-SMAD signaling (Dorsomorphin or LDN1931890) or transducing inhibitory SMADs (SMAD6 or SMAD7). In normal fibroblasts, the efficiency of iPSC generation was enhanced by transducing mutant ACVR1 (617G > A) or SMAD1 or adding BMP4 protein at early times during the reprogramming. In contrast, adding BMP4 at later times decreased iPSC generation. ID genes, transcriptional targets of BMP-SMAD signaling, were critical for iPSC generation. The BMP-SMAD-ID signaling axis suppressed p16/INK4A-mediated cell senescence, a major barrier to reprogramming. These results using patient cells carrying the ACVR1 R206H mutation reveal how cellular signaling and gene expression change during the reprogramming processes. Significance The development of iPSCs provides unprecedented opportunities for life sciences, drug discovery, and regenerative medicine. The efficiency of iPSC generation is quite low: typically less than 1% of human primary somatic cells that have received reprogramming factors turn into iPSCs. Previous studies revealed that cellular senescence was a major barrier to iPSC generation. In this study using human FOP mutant cells, we provide evidence that the BMP-SMAD-ID signaling suppressed p16/INK4A-mediated cellular senescence during the early phase in iPSC generation. These results are unexpected because BMP-SMAD signaling has negative effects on the self-renewal of human iPSCs. Here, we show that a human natural mutation increases the efficiency of iPSC generation.
- 13 October 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (44) , 12478-12483
Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program
Developmental signaling molecules are used for cell fate determination, and understanding how their combinatorial effects produce the variety of cell types in multicellular organisms is a key problem in biology. Here, we demonstrate that the combination of leukemia inhibitory factor (LIF), bone morphogenetic protein 4 (BMP4), lysophosphatidic acid (LPA), and ascorbic acid (AA) efficiently converts mouse primed pluripotent stem cells (PSCs) into naive PSCs. Signaling by the lipid LPA through its receptor LPAR1 and downstream effector Rho-associated protein kinase (ROCK) cooperated with LIF signaling to promote this conversion. BMP4, which also stimulates conversion to naive pluripotency, bypassed the need for exogenous LPA by increasing the activity of the extracellular LPA-producing enzyme autotaxin (ATX). We found that LIF and LPA-LPAR1 signaling affect the abundance of signal transducer and activator of transcription 3 (STAT3), which induces a previously unappreciated Kruppel-like factor (KLF)2-KLF4-PR domain 14 (PRDM14) transcription factor circuit key to establish naive pluripotency. AA also affects this transcription factor circuit by controlling PRDM14 expression. Thus, our study reveals that ATX-mediated autocrine lipid signaling promotes naive pluripotency by intersecting with LIF and BMP4 signaling.
- 13 October 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (44) , 12478-12483
Autotaxin-mediated lipid signaling intersects with LIF and BMP signaling to promote the naive pluripotency transcription factor program
Developmental signaling molecules are used for cell fate determination, and understanding how their combinatorial effects produce the variety of cell types in multicellular organisms is a key problem in biology. Here, we demonstrate that the combination of leukemia inhibitory factor (LIF), bone morphogenetic protein 4 (BMP4), lysophosphatidic acid (LPA), and ascorbic acid (AA) efficiently converts mouse primed pluripotent stem cells (PSCs) into naive PSCs. Signaling by the lipid LPA through its receptor LPAR1 and downstream effector Rho-associated protein kinase (ROCK) cooperated with LIF signaling to promote this conversion. BMP4, which also stimulates conversion to naive pluripotency, bypassed the need for exogenous LPA by increasing the activity of the extracellular LPA-producing enzyme autotaxin (ATX). We found that LIF and LPA-LPAR1 signaling affect the abundance of signal transducer and activator of transcription 3 (STAT3), which induces a previously unappreciated Kruppel-like factor (KLF)2-KLF4-PR domain 14 (PRDM14) transcription factor circuit key to establish naive pluripotency. AA also affects this transcription factor circuit by controlling PRDM14 expression. Thus, our study reveals that ATX-mediated autocrine lipid signaling promotes naive pluripotency by intersecting with LIF and BMP4 signaling.
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e77
Establishment and characterization of iPS cells derived from XPA patients
- 1 October 2016
- Published by Elsevier in Journal of Dermatological Science
- Vol. 84 (1) , e77
Establishment and characterization of iPS cells derived from XPA patients